Eli Lilly Plans Regulatory Filings for Tirzepatide After Cardio Success

Lilly's tirzepatide has demonstrated its promise in another significant health condition, as the company works to expand its manufacturing capabilities for the drug. The dual GIP/GLP-1 receptor agonist has already shown effectiveness in treating diabetes, obesity, sleep apnea, and fatty liver disease. Recently, Eli Lilly reported favorable outcomes from a clinical trial in patients suffering from heart failure (HF).

In the phase 3 SUMMIT trial, tirzepatide significantly lowered the risk of adverse heart failure events—such as hospitalization or cardiovascular death—by 38% compared to a placebo. The study involved 731 patients diagnosed with heart failure with preserved ejection fraction (HFpEF) and obesity. Besides achieving the primary goal of reducing HF events, tirzepatide also enhanced patients' heart failure symptoms and physical limitations compared to placebo. This secondary objective was measured using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score.

HFpEF, a condition where the left ventricle of the heart becomes stiff and fails to fill properly between beats, impacts blood flow. According to Lilly, HFpEF represents nearly half of all heart failure cases. Symptoms commonly include fatigue, shortness of breath, exercise intolerance, and swelling. Importantly, almost 60% of HFpEF patients also struggle with obesity, noted Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly.

In addition to the main outcomes, tirzepatide met all secondary aims of the study, including a metric for improved exercise capacity. Furthermore, patients treated with tirzepatide experienced substantial weight reduction, losing an average of 15.7% of their body weight before stopping the treatment, compared to just 2.2% for those on placebo.

Lilly plans to present the trial results at an upcoming medical conference and aims to publish them in a peer-reviewed journal. Tirzepatide is already approved for Type 2 diabetes under the brand name Mounjaro and for obesity as Zepbound, with expectations of significant blockbuster sales in these areas. Lilly intends to submit the SUMMIT study results to the FDA and other global regulatory bodies later this year, potentially bolstering the drug's market performance.

In the competitive landscape, tirzepatide is rivaled by Novo Nordisk's GLP-1 drug semaglutide. Branded as Ozempic and Rybelsus for diabetes and Wegovy for obesity, semaglutide showed positive results in a late-stage trial for HFpEF patients last year, leading the FDA to approve a cardio label expansion for the drug in March.

Given the soaring demand for these competing medications, both Novo Nordisk and Lilly have invested billions in expanding their global manufacturing capacities. Recently, Lilly pledged over $9 billion to increase tirzepatide production in its home state of Indiana in response to the drug's high demand.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!